PMID- 30228238
OWN - NLM
STAT- MEDLINE
DCOM- 20190304
LR  - 20191227
IS  - 2150-7511 (Electronic)
VI  - 9
IP  - 5
DP  - 2018 Sep 18
TI  - The Microbiome and Tuberculosis: Early Evidence for Cross Talk.
LID - 10.1128/mBio.01420-18 [doi]
LID - e01420-18
AB  - Tuberculosis (TB) is an ancient infectious disease of humans that has been 
      extensively studied both clinically and experimentally. Although susceptibility 
      to Mycobacterium tuberculosis infection is clearly influenced by factors such as 
      nutrition, immune status, and both mycobacterial and host genetics, the variable 
      pathogenesis of TB in infected individuals remains poorly understood. During the 
      past two decades, it has become clear that the microbiota-the trillion organisms 
      that reside at mucosal surfaces within and on the body-can exert a major 
      influence on disease outcome through its effects on host innate and adaptive 
      immune function and metabolism. This new recognition of the potentially 
      pleiotropic participation of the microbiome in immune responses has raised the 
      possibility that the microbiota may influence M. tuberculosis infection and/or 
      disease. Similarly, treatment of TB may alter the healthy steady-state 
      composition and function of the microbiome, possibly affecting treatment outcome 
      in addition to other host physiological parameters. Herein, we review emerging 
      evidence for how the microbiota may influence the transition points in the life 
      cycle of TB infection, including (i) resistance to initial infection, (ii) 
      initial infection to latent tuberculosis (LTBI), (iii) LTBI to reactivated 
      disease, and (iv) treatment to cure. A major goal of this review is to frame 
      questions to guide future scientific and clinical studies in this largely 
      unexplored but increasingly important area of TB research.
FAU - Namasivayam, Sivaranjani
AU  - Namasivayam S
AUID- ORCID: 0000-0001-9993-1347
AD  - Immunobiology Section, Laboratory of Parasitic Diseases, National Institute of 
      Allergy and Infectious Diseases, National Institutes of Health, Bethesda, 
      Maryland, USA.
FAU - Sher, Alan
AU  - Sher A
AUID- ORCID: 0000-0001-7053-2895
AD  - Immunobiology Section, Laboratory of Parasitic Diseases, National Institute of 
      Allergy and Infectious Diseases, National Institutes of Health, Bethesda, 
      Maryland, USA asher@niaid.nih.gov glickmam@mskcc.org.
FAU - Glickman, Michael S
AU  - Glickman MS
AUID- ORCID: 0000-0001-7918-5164
AD  - Immunology Program, Memorial Sloan Kettering Cancer Center, New York, New York, 
      USA asher@niaid.nih.gov glickmam@mskcc.org.
AD  - Infectious Diseases Service, Department of Medicine, Memorial Sloan Kettering 
      Cancer Center, New York, New York, USA.
FAU - Wipperman, Matthew F
AU  - Wipperman MF
AUID- ORCID: 0000-0003-1436-3366
AD  - Immunology Program, Memorial Sloan Kettering Cancer Center, New York, New York, 
      USA.
AD  - Clinical and Translational Science Center, Weill Cornell Medical College, New 
      York, New York, USA.
LA  - eng
GR  - U19 AI111143/AI/NIAID NIH HHS/United States
GR  - TL1 TR002386/TR/NCATS NIH HHS/United States
GR  - P30 CA008748/CA/NCI NIH HHS/United States
GR  - UL1 TR002384/TR/NCATS NIH HHS/United States
GR  - UL1 TR000457/TR/NCATS NIH HHS/United States
PT  - Journal Article
PT  - Research Support, N.I.H., Extramural
PT  - Research Support, N.I.H., Intramural
PT  - Review
DEP - 20180918
PL  - United States
TA  - mBio
JT  - mBio
JID - 101519231
RN  - 0 (Antitubercular Agents)
RN  - 0 (Bacterial Proteins)
SB  - IM
MH  - Animals
MH  - Antitubercular Agents/therapeutic use
MH  - Bacterial Proteins
MH  - Disease Progression
MH  - Gastrointestinal Microbiome/drug effects/immunology
MH  - Host Microbial Interactions
MH  - Humans
MH  - Latent Tuberculosis/drug therapy/immunology/microbiology
MH  - Mice
MH  - *Microbiota
MH  - Mycobacterium tuberculosis/immunology
MH  - Tuberculosis/drug therapy/*immunology/*microbiology
PMC - PMC6143735
OTO - NOTNLM
OT  - antibiotics
OT  - microbiome
OT  - tuberculosis
EDAT- 2018/09/20 06:00
MHDA- 2019/03/05 06:00
PMCR- 2018/09/18
CRDT- 2018/09/20 06:00
PHST- 2018/09/20 06:00 [entrez]
PHST- 2018/09/20 06:00 [pubmed]
PHST- 2019/03/05 06:00 [medline]
PHST- 2018/09/18 00:00 [pmc-release]
AID - mBio.01420-18 [pii]
AID - mBio01420-18 [pii]
AID - 10.1128/mBio.01420-18 [doi]
PST - epublish
SO  - mBio. 2018 Sep 18;9(5):e01420-18. doi: 10.1128/mBio.01420-18.